Daiichi Sankyo, Inc. and Merck & Co, Inc. - Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist’s Evolving Role
Speaker(s)
Kristin Higgins, MD - City of Hope Atlanta
Alyssa Cooper, MD - Dana-Farber Cancer Institute
Percy Lee, MD, FASTRO - City of Hope National Medical Center
session DESCRIPTION
This educational activity is directed toward radiation oncologists (primary), with medical oncologists, APPs, oncology nurses, and pharmacists managing ES-SCLC. Dinner will be provided. For more information, please visit www.astro.org/ISS.
learning objectives
Evaluate emerging systemic therapies for extensive-stage SCLC across lines of therapy.
Apply evidence on the intracranial activity of emerging agents to individualize treatment.
Differentiate and co-manage treatment-related adverse events.
Credits
| AMA PRA Category 1 Credits: | Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours for nurses. |